BFIC
ALXN

Bedell Frazier Investment Counselling’s Alexion Pharmaceuticals ALXN Stock Holding History

Bedell Frazier Investment Counselling’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-36,328
Closed -$4.83M – 62
2013
Q4 		$4.83M Sell
36,328
-207
-0.6% -$24.8K 2.27% 15
2013
Q3 		$4.24M Buy
36,535
+405
+1% +$44.4K 2.04% 19
2013
Q2 		$3.95M Buy
+36,130
New +$3.48M 1.96% 19

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Bedell Frazier Investment Counselling's ALXN Position: Q1 2014 in Review

Bedell Frazier Investment Counselling sold out of Alexion Pharmaceuticals (ALXN) in Q1 2014, closing a stake of 36,328 shares — an estimated $4.83M sold.

Bedell Frazier Investment Counselling first reported a position in ALXN in Q2 2013 and held it in 3 quarters. The position peaked at $4.83M in Q4 2013. 504 funds tracked by Wall St. Rank hold ALXN as of Q1 2014.

  • Bedell Frazier Investment Counselling reported no remaining Alexion Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Bedell Frazier Investment Counselling sold 36,328 Alexion Pharmaceuticals shares in Q1 2014, an estimated $4.83M.
  • Bedell Frazier Investment Counselling first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Bedell Frazier Investment Counselling's Alexion Pharmaceuticals position peaked at $4.83M in Q4 2013.
  • 504 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2014.

Based on Bedell Frazier Investment Counselling's 13F filing for Q1 2014, filed 23 Apr 2014.